Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Phase 2 Study of the Safety and Efficacy of Dupilumab as Add-on Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents

Next Previous
Trial Profile

A Pilot Phase 2 Study of the Safety and Efficacy of Dupilumab as Add-on Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Benralizumab (Primary) ; Dupilumab (Primary) ; Mepolizumab (Primary) ; Reslizumab (Primary)
  • Indications Hypereosinophilic syndrome
  • Focus Therapeutic Use

Most Recent Events

  • 07 Feb 2025 Planned initiation date changed from 5 Feb 2025 to 12 Feb 2025.
  • 31 Jan 2025 Planned initiation date changed from 29 Jan 2025 to 5 Feb 2025.
  • 24 Jan 2025 Planned initiation date (estimated date for recruitment of the first subject) changed to 29 Jan 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top